JB Pharma Sustainability report 2024 has released. The company announced its ESG commitments with the launch of its 3rd Sustainability (ESG) Report. This marks a significant step forward in the company’s ongoing dedication to sustainability, aimed at driving environmental and social progress.
JB Pharma Sustainability report 2024 highlights the company’s achievements in reducing its environmental impact and improving resource efficiency. The company has successfully reduced emissions (Scope 1 & Scope 2) intensity per rupee of turnover by 22.2%, while total Scope 1 and Scope 2 absolute emissions decreased by 13.9%.
Renewable energy played a key role for JB Pharma with JB generating 46341 GJ of energy from renewable sources of energy, which is 12.1% of total energy demand. Additionally, it has avoided 9,216.7 tCO2e emissions through renewable sources, reducing its total energy consumption by 5.7% and lowering its energy intensity per rupee of turnover by 14.8%.
Water consumption intensity per rupee of turnover also dropped by 4.8%. Waste sent to landfill decreased to 12.2%, down from 17.18% in the previous year. All manufacturing facilities have achieved Zero Liquid Discharge (ZLD), further emphasizing the company’s environmental stewardship.
Nikhil Chopra, CEO and Whole Time Director, JB Pharma said, “Guided by the theme ‘Building a Sustainable Future for Good Health,’ happy to announce the release of JB Pharma’s 3rd Sustainability Report FY24. We recognize the vital connection between sustainability and public health. This report showcases our ongoing journey towards sustainability, highlighting our innovative strategies and dedication to fostering a healthier and more resilient world. As part of our steadfast commitment to environmental stewardship and social well-being, we are thrilled to have undertaken its inaugural ESG Goals and Targets, reinforcing our commitment to sustainable growth. These targets not only prioritize the most impactful ESG KPIs for our business and stakeholders but also guides our strategies towards long-term value creation”.
Keeping employee growth and wellness at the core, JB Pharma has developed an extensive DE&I (diversity, equity and inclusion) framework that ensures a fair and equitable environment for all, driving innovation and organizational success.
As per the press release, by setting ambitious targets and implementing sustainable practices, the company aims to strengthen its leadership in the pharmaceutical industry, driving progress towards a healthier, more resilient, and sustainable future for all.
